Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Cash from Financing Activities: 2018-2024

Historic Cash from Financing Activities for Avidity Biosciences (RNA) over the last 7 years, with Dec 2024 value amounting to $1.2 billion.

  • Avidity Biosciences' Cash from Financing Activities rose 148.31% to $850.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $869.8 million, marking a year-over-year decrease of 28.15%. This contributed to the annual value of $1.2 billion for FY2024, which is 1170.30% up from last year.
  • According to the latest figures from FY2024, Avidity Biosciences' Cash from Financing Activities is $1.2 billion, which was up 1,170.30% from $93.9 million recorded in FY2023.
  • In the past 5 years, Avidity Biosciences' Cash from Financing Activities registered a high of $1.2 billion during FY2024, and its lowest value of $93.9 million during FY2023.
  • Over the past 3 years, Avidity Biosciences' median Cash from Financing Activities value was $346.2 million (recorded in 2022), while the average stood at $544.1 million.
  • Per our database at Business Quant, Avidity Biosciences' Cash from Financing Activities slumped by 72.89% in 2023 and then surged by 1,170.30% in 2024.
  • Avidity Biosciences' Cash from Financing Activities (Yearly) stood at $272.0 million in 2020, then crashed by 35.19% to $176.3 million in 2021, then soared by 96.34% to $346.2 million in 2022, then plummeted by 72.89% to $93.9 million in 2023, then soared by 1,170.30% to $1.2 billion in 2024.